“Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges. I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value.”


*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

/one.numr Non-GAAP measure; excludes the impact of translational currency.

two.numr Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes.

Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-Looking Statements” included in the Johnson & Johnson earnings release issued on January 24, 2023 as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

### Full Year 2022 Results

#### 2022 Sales

<table>
<thead>
<tr>
<th>Segment</th>
<th>Sales</th>
<th>Change</th>
<th>Adjusted Diluted Earnings Per Share*</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Worldwide</td>
<td>$94.9B</td>
<td>1.3%</td>
<td>$10.15</td>
<td>3.6%</td>
</tr>
<tr>
<td>Excluding acquisitions/ divestitures on an operational basis</td>
<td>$94.9B</td>
<td>1.3%</td>
<td>$10.15</td>
<td>3.6%</td>
</tr>
</tbody>
</table>

#### Diluted Earnings Per Share

<table>
<thead>
<tr>
<th>Year</th>
<th>Amount</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>2022</td>
<td>$6.73</td>
<td>(13.8)%</td>
</tr>
</tbody>
</table>

#### Worldwide Consumer Health Sales

Consumer Health worldwide reported sales decreased (0.0)%, but increased 3.6% operationally.

Primary operational drivers:

- Motrin
- TYLENOL
- imodium
- Neutrogena
- SUDAFED
- ob.

#### Worldwide Pharmaceutical Sales

Pharmaceutical worldwide reported sales increased 1.7% or 6.7% operationally.

Primary operational drivers:

- DARZALEX
- STELLARA
- INGRAVE SUSTENSA
- Tremfya
- Upatre

#### Worldwide MedTech Sales

MedTech worldwide reported sales increased 1.4% or 6.2% operationally.

Primary operational drivers:

- Electrolysis
- Contact Lense
- Wound Closure
- Surgical Vision
- Transfix
- Hip
- Knee
- Biosurgery
- Endoscopes
- Energy

Note: values may have been rounded; the MedTech segment was previously referred to as the Medical Devices segment.